Progression of Cutaneous T-Cell Lymphoma after dupilumab: Case review of 7 patients

Supplement 1: Report of Cases Seven patients were prescribed dupilumab for chronic recalcitrant presumed AD (cases 1-4), or as an off-label treatment for patients with MF and severe pruritus (cases 5-7). In all 7 patients, the standard dosing regimen for dupilumab was followed (600mg loading dose, followed by 300mg every 2 weeks subcutaneously). Case vignettes and photographs found below.